News
GLP-1s (glucagon-like peptide-1 receptor agonists), like Wegovy, Ozempic, or generic liraglutide, have helped you reach your ...
The research suggests that liraglutide, a drug originally developed for diabetes (Victoza) and weight management (Saxenda), may significantly reduce the frequency of debilitating migraine.
14d
The Hearty Soul on MSNA New Ozempic-like drug Side Effect Has Just Been Discovered-And It's Turning Lives Upside Down
Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...
Mumbai: Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) ...
20d
Best Life on MSNScientists Discover Another Major Weight-Loss Drug Side Effect—But This Time, It’s Good
A new study found that GLP-1 weight-loss drugs with the active ingredient liraglutide can significantly reduce migraines.
Lupin receives USFDA approval for generic diabetes medications, including Liraglutide Injection and Glucagon for Injection.
Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.
Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...
Furthermore, the liraglutide group demonstrated significantly larger reductions in weight, waist circumference, systolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol.
Liraglutide concentrations were measured with a radioimmunoassay specific for the intact N-terminus of GLP-1 using liraglutide as standard and antibody code no. 98302. 10 This assay would in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results